EX-32.2 10 cgtx-20241231xex32d2.htm EX-32.2

Exhibit 32.2

STATEMENT PURSUANT TO

18 U.S.C. SECTION 1350

AS REQUIRED BY

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

​

In connection with the Annual Report of Cognition Therapeutics, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify that to the best of our knowledge:

​

| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

​

| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

​

​ | ​ | ​ | ​
​ March 20, 2025 | ​ /s/ John Doyle | ​ | Chief Financial Officer (Principal Financial Officer and Principal
​ | John Doyle | ​ | Accounting Officer) ​

​

A signed original of this written statement required by Section 906 has been provided to Cognition Therapeutics, Inc. and will be retained by Cognition Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.